Attachment
Guidelines to be observed when using iPS cells and their derivative cells produced by use of the Sendai virus vector (SeV-iPS cells)

SeV-iPS cells are produced based on the intellectual property owned by DNAVEC Corporation (hereinafter referred to as 'DNAVEC'). They are provided without license fees exclusively for non-profit academic research at academic institutions.

Academic Institutions are universities and agencies of a government (Federal or State) that perform research.

  The following guidelines must be observed when using SeV-iPS cells:
1. Even if you are a non-profit academic institution, you must contact DNAVEC beforehand in the following cases:
   a. When you plan to use SeV-iPS cells for for-profit non-academic research purposes.
   b. When you plan to use SeV-iPS cells for collaborative research with a for-profit organization.
2. You may not redistribute SeV-iPS cells to third parties. If a third party expresses an interest in using SeV-iPS cells, please ask them to contact the RIKEN BRC directly.
The use of SeV-iPS cells for purposes other than non-profit academic research is strictly prohibited as defined below.
1. Commercial, non-academic contract research services for a compensatory fee that provide SeV-iPS (including derivatives), services, information (including targets identified), research results, instruments and apparatuses produced by use of the Sendai virus vector, unless the third party has obtained an appropriate license for commercial use from DNAVEC;
2. Screening (conventional or high-throughput) of candidate compounds for development of therapeutics, except when performed by or on behalf of an academic institution for internal not-commercially sponsored research or on behalf of a third party that has obtained an appropriate license from DNAVEC;
3. Applied research development and manufacture of therapeutics, diagnostics, and prophylactics (e.g., hit-to-lead, lead optimization), except when performed on behalf of a third party that has obtained an appropriate license from DNAVEC;
4. Non-human safety studies except when performed on behalf of an academic institution for internal not-commercially sponsored research or on behalf of a third party that has obtained an appropriate license from DNAVEC;
5. Transfer of SeV-iPS cells to collaborators carrying out commercially sponsored compound screening or applied research development research (including a collaborator from a commercial entity), unless the sponsor or commercial entity has obtained an appropriate commercial license from DNAVEC;
6. Commercialization of drug candidates, SeV-iPS cells, equipment or cell culture media made using the Sendai virus vector without appropriate commercial license from DNAVEC.
Inquiries
DNAVEC Corporation
6 Ohkubo, Tsukuba, Ibaraki Prefecture, 300-2611
Tel: +81-29-877-5155, Fax: +81-29-877-5160
Email: cytotune@dnavec-corp.com